Loading...

ACRS ACLARIS THERAPEUTICS INC Expansion Plans 8-K Filing

CLRS

CRS

ACLARIS THERAPEUTICS INC

(ACRS)

2026 8-K

Stock Sale Announcement

Stock Sale Update

Financial Results Announced

Corporate Update

Phase 1 Results

Financial Results Update

R&D Day Announcement

Financial Statements

Clinical Trials

Investor Meetings

Increase in authorized shares

Financial Statements

Financial Results

Corporate Update

Licensing and Funding

Financial Results

Financial Results Announcement

Agreement with OMERS

Annual Meeting Results

Departure of Directors

Financial Results Announcement

Amendment to Filing

Management Changes

Financial Results and Manag...

Workforce Reduction

Conference Call and Press R...

Financial Results Announcement

Phase 1 trial results

Financial Results Announcement

Amended Employment Agreement

Annual Meeting Results

Lease Agreement

Amendment to Consulting Ser...

Clinical Trial Results

Sales Agreement and Termina...

Financial Results Announcement

Presentation at Investor Co...

Employment Agreements

External Links:

On January 6, 2026, Aclaris Therapeutics reported favorable interim results from its Phase 1a trial of ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, indicating good safety and a potential for up to every three-month dosing.

AI Assistant

ACLARIS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.